Hospitalizations and healthcare costs associated with rifaximin versus lactulose treatment among commercially insured patients with hepatic encephalopathy in the United States.
Sign Up to like & getrecommendations! Published in 2021 at "Journal of medical economics"
DOI: 10.1080/13696998.2021.1877148
Abstract: AIMS To assess healthcare costs and hospitalization rates associated with rifaximin therapy versus lactulose alone among patients at risk for hepatic encephalopathy (HE). METHODS AND MATERIALS IBM Marketscan® Commercial and Optum's de-identified Clinformatics® Data Mart… read more here.
Keywords: associated rifaximin; healthcare costs; versus lactulose; lactulose alone ... See more keywords
Combination therapy with rifaximin and lactulose in hepatic encephalopathy: A systematic review and meta-analysis
Sign Up to like & getrecommendations! Published in 2022 at "PLoS ONE"
DOI: 10.1371/journal.pone.0267647
Abstract: Rifaximin and lactulose are widely used in patients with hepatic encephalopathy (HE); however, data on whether the combined use of rifaximin and lactulose could yield additional benefits for patients with HE are limited and inconclusive.… read more here.
Keywords: rifaximin lactulose; rifaximin; lactulose alone; systematic review ... See more keywords